NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS)

Trial Profile

NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs NGR-TNF (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors MolMed
  • Most Recent Events

    • 12 Jun 2016 Status is completed in Italy (End date: 2016-05-09) as per European Clinical Trials Database record.
    • 05 Apr 2015 Planned End Date changed from 1 Dec 2013 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
    • 05 Apr 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top